Compare Stocks → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BCDANASDAQ:BCLINYSEMKT:PHGENASDAQ:PHXM Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCDABioCardia$4.62-11.2%$5.69$4.35▼$43.80$8.41M1.4711,563 shs48,259 shsBCLIBrainstorm Cell Therapeutics$0.49-5.8%$0.54$0.13▼$3.34$34.10M0.4537,161 shs403,824 shsPHGEBiomX$0.40-4.8%$0.36$0.00▼$0.00$27.92M1.3168,601 shs300,741 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/A20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCDABioCardia0.00%-10.98%-17.87%-46.88%-82.60%BCLIBrainstorm Cell Therapeutics0.00%-9.44%+22.17%+40.96%-82.93%PHGEBiomX-2.42%+17.65%-1.96%+87.79%+12.14%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%+10.32%+309,999,900.00%Trump’s Gift Could Unleash $51 Billion in New Wealth (Ad)In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCDABioCardia2.2538 of 5 stars3.34.00.00.02.62.50.0BCLIBrainstorm Cell Therapeutics1.7263 of 5 stars0.05.00.04.72.90.00.6PHGEBiomX1.7701 of 5 stars3.50.00.00.01.01.71.3PHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCDABioCardia2.50Moderate Buy$60.001,198.70% UpsideBCLIBrainstorm Cell Therapeutics2.00HoldN/AN/APHGEBiomX3.00Buy$2.25462.50% UpsidePHXMPHAXIAM TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest PHGE, BCDA, PHXM, and BCLI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2024BCDABioCardiaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.005/28/2024PHGEBiomXLaidlawSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$2.505/21/2024PHGEBiomXHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.004/22/2024PHGEBiomXHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.00(Data available from 6/2/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCDABioCardia$480K17.52N/AN/A($1.25) per share-3.70BCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($0.08) per shareN/APHGEBiomXN/AN/AN/AN/A$0.70 per shareN/APHXMPHAXIAM Therapeutics$32.66M0.32N/AN/A$7.98 per share0.39Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCDABioCardia-$11.57M-$7.05N/AN/AN/A-2,208.76%-3,638.68%-261.66%8/14/2024 (Estimated)BCLIBrainstorm Cell Therapeutics-$17.19M-$0.32N/AN/AN/AN/AN/A-431.16%8/12/2024 (Estimated)PHGEBiomX-$28.32M-$0.61N/AN/AN/AN/A-127.82%-56.50%N/APHXMPHAXIAM Therapeutics-$240KN/A0.00∞N/AN/AN/AN/AN/ALatest PHGE, BCDA, PHXM, and BCLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2024Q1 2024BCDABioCardiaN/A-$1.35-$1.35-$0.09N/A$0.06 million 5/14/2024Q1 2024BCLIBrainstorm Cell Therapeutics-$0.07-$0.05+$0.02-$0.05N/AN/A4/1/2024Q4 2023BCLIBrainstorm Cell Therapeutics-$0.15-$0.11+$0.04-$0.11N/AN/A3/27/2024Q4 2023BCDABioCardia-$1.65-$1.35+$0.30-$0.09$0.20 million$0.01 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCDABioCardiaN/AN/AN/AN/AN/ABCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/APHGEBiomXN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCDABioCardiaN/A0.310.31BCLIBrainstorm Cell TherapeuticsN/A0.180.18PHGEBiomX0.512.842.84PHXMPHAXIAM Therapeutics0.231.78N/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCDABioCardia20.57%BCLIBrainstorm Cell Therapeutics14.33%PHGEBiomX40.57%PHXMPHAXIAM Therapeutics0.40%Insider OwnershipCompanyInsider OwnershipBCDABioCardia20.00%BCLIBrainstorm Cell Therapeutics5.45%PHGEBiomX4.21%PHXMPHAXIAM Therapeutics1.94%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBCDABioCardia161.82 million1.46 millionOptionableBCLIBrainstorm Cell Therapeutics2970.08 million66.26 millionOptionablePHGEBiomX5869.81 million44.04 millionNot OptionablePHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataPHGE, BCDA, PHXM, and BCLI HeadlinesRecent News About These CompaniesMay 15, 2024 | finanznachrichten.dePhaxiam Therapeutics S.A.: PHAXIAM provides Business and Financial Update for the First Quarter of 2024May 15, 2024 | globenewswire.comPHAXIAM provides Business and Financial Update for the First Quarter of 2024April 15, 2024 | msn.comPhaxiam enrols first patient in endocarditis infection studyApril 15, 2024 | globenewswire.comPHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureusApril 5, 2024 | finanznachrichten.dePhaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)April 5, 2024 | globenewswire.comPHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)March 23, 2024 | seekingalpha.comONCT Oncternal Therapeutics, Inc.March 20, 2024 | globenewswire.comPHAXIAM Announces 2023 Full-Year Results and Provides Business UpdateMarch 11, 2024 | finanznachrichten.dePhaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock MarketMarch 11, 2024 | markets.businessinsider.comPhaxiam Therapeutics Says Delisting Of ADSs From Nasdaq EffectiveMarch 11, 2024 | globenewswire.comPHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock MarketMarch 5, 2024 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital - February 29, 2024February 20, 2024 | globenewswire.comPHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital MarketFebruary 7, 2024 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital - January 31, 2024January 19, 2024 | finanznachrichten.dePhaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024January 18, 2024 | finance.yahoo.comPHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024January 3, 2024 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital - December 31, 2023December 6, 2023 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital - November 30, 2023November 28, 2023 | lse.co.ukPhaxiam Therapeutics Share Price (PHXM.PA)November 15, 2023 | finanznachrichten.dePhaxiam Therapeutics S.A.: PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023New MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBioCardiaNASDAQ:BCDABioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. BioCardia, Inc. is based in Sunnyvale, California.Brainstorm Cell TherapeuticsNASDAQ:BCLIBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.BiomXNYSEMKT:PHGEBiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.PHAXIAM TherapeuticsNASDAQ:PHXMPHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.